ES2237842T3 - Uso de los derivados de la alcanoil carnitina en el tratamiento de los trastornos de deficit de atencion con hiperactividad. - Google Patents

Uso de los derivados de la alcanoil carnitina en el tratamiento de los trastornos de deficit de atencion con hiperactividad.

Info

Publication number
ES2237842T3
ES2237842T3 ES98932502T ES98932502T ES2237842T3 ES 2237842 T3 ES2237842 T3 ES 2237842T3 ES 98932502 T ES98932502 T ES 98932502T ES 98932502 T ES98932502 T ES 98932502T ES 2237842 T3 ES2237842 T3 ES 2237842T3
Authority
ES
Spain
Prior art keywords
carnitine
acid
alkanoyl
treatment
adhd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98932502T
Other languages
English (en)
Spanish (es)
Inventor
Claudio Cavazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of ES2237842T3 publication Critical patent/ES2237842T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES98932502T 1997-07-22 1998-07-08 Uso de los derivados de la alcanoil carnitina en el tratamiento de los trastornos de deficit de atencion con hiperactividad. Expired - Lifetime ES2237842T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US898433 1997-07-22
US08/898,433 US5869528A (en) 1997-07-22 1997-07-22 Therapeutical method for the treatment of attention-deficit/hyperactive disorders

Publications (1)

Publication Number Publication Date
ES2237842T3 true ES2237842T3 (es) 2005-08-01

Family

ID=25409451

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98932502T Expired - Lifetime ES2237842T3 (es) 1997-07-22 1998-07-08 Uso de los derivados de la alcanoil carnitina en el tratamiento de los trastornos de deficit de atencion con hiperactividad.

Country Status (12)

Country Link
US (1) US5869528A (https=)
EP (1) EP0998276B1 (https=)
JP (1) JP4276779B2 (https=)
KR (1) KR100530879B1 (https=)
AT (1) ATE290376T1 (https=)
AU (1) AU735697B2 (https=)
CA (1) CA2297153C (https=)
DE (1) DE69829290T2 (https=)
ES (1) ES2237842T3 (https=)
NZ (1) NZ501966A (https=)
PT (1) PT998276E (https=)
WO (1) WO1999004785A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
DK0951909T4 (da) 1998-03-19 2011-01-24 Sigma Tau Ind Farmaceuti Kombinationspræparat omfattende en L-carnitin eller en alkanoyl-L-carnitin, en glycosaminoglycan og/eller bestanddel deraf
US6204291B1 (en) 1998-06-26 2001-03-20 The Iams Company Process for promoting weight loss in overweight dogs
US6630159B2 (en) * 1999-02-23 2003-10-07 The Procter & Gamble Company Limiting weight gain of cats by feeding carbohydrate source that excludes rice
US7001618B1 (en) 1999-07-09 2006-02-21 The Iams Company Nutritional composition for weight management
WO2001028554A1 (en) * 1999-10-20 2001-04-26 Thomas Jefferson University Treatment of attention deficit disorder and impaired visual-spatial function with androgen
ITRM20010218A1 (it) * 2001-04-23 2002-10-23 Sigma Tau Healthscience Spa Composizione per la prevenzione o il trattamento dei disturbi dell'apprendimento in bambini affetti da deficit dell'attenzione ed iperattivi
JP4812968B2 (ja) * 2001-06-06 2011-11-09 太陽化学株式会社 注意欠陥多動性障害改善用組成物
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
AU2016219070B2 (en) 2015-02-13 2020-06-11 Mars, Incorporated Pet food feeding system

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism

Also Published As

Publication number Publication date
US5869528A (en) 1999-02-09
HK1028546A1 (en) 2001-02-23
KR20010022008A (ko) 2001-03-15
JP4276779B2 (ja) 2009-06-10
CA2297153C (en) 2007-07-03
WO1999004785A1 (en) 1999-02-04
EP0998276B1 (en) 2005-03-09
AU8240598A (en) 1999-02-16
ATE290376T1 (de) 2005-03-15
AU735697B2 (en) 2001-07-12
PT998276E (pt) 2005-06-30
DE69829290D1 (de) 2005-04-14
CA2297153A1 (en) 1999-02-04
DE69829290T2 (de) 2006-04-13
NZ501966A (en) 2001-12-21
JP2001510800A (ja) 2001-08-07
KR100530879B1 (ko) 2005-11-23
EP0998276A1 (en) 2000-05-10

Similar Documents

Publication Publication Date Title
ES2395462T3 (es) Inhibidores selectivos de la recaptación de norepinefrina-serotonina para el tratamiento del síndrome de fibromialgia, síndrome de fatiga crónica y dolor
US4346107A (en) Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
ES2289787T3 (es) Administracion en larga duracion en embolada de d-treo-metilfenidato.
ES2731228T3 (es) Acido benzoico o sales del mismo para mejorar la actividad de un producto farmacéutico
ES2392580T3 (es) Comprimidos que contienen entre 250 y 450 mg de modafinilo
ES2237842T3 (es) Uso de los derivados de la alcanoil carnitina en el tratamiento de los trastornos de deficit de atencion con hiperactividad.
US6359005B1 (en) Method for the treatment of mania and bipolar disorder
JPH04502161A (ja) 緑内障の治療処置におけるアセチルｄ―カルニチンの用途
Tabor et al. Corneal damage due to eye contact with chlorhexidine gluconate
EP0825857B1 (en) Use of gabapentin and its derivatives in the treatment of mania and bipolar disorder
KR100346883B1 (ko) 만성폐색성동맥경화증의치료에유용한카르니틴유도체-함유약제
LENNOX The drug therapy of epilepsy
Fehling The effect of adding amantadine to optimum l‐dopa dosage in Parkinson's syndrome
EP0756869A2 (en) Use of duloxetine or of N-alkyl-3-phenyl-(2-alkylthiophenoxy)-propylamines for treating attention-deficit/hyperactivity disorder
ES3004543T3 (en) Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
MXPA98000589A (en) Treatment of disorder of lack of attention / hyperactivi
JP4746714B2 (ja) 線維筋痛症治療用医薬組成物
Chen A COMPARATIVE STUDY OF EPHEDRINE, PSEUDO-EPHEDRINE AND ß-PHENYL-ETHYLAMINE: WITH REFERENCE TO THEIR EFFECTS ON THE PUPIL AND ON THE BLOOD PRESSURE
ES3038949T3 (en) Compounds for use in the treatment of attention deficit hyperactivity disorder
ES2237591T3 (es) Composicion que contiene carnitina y huperzina para la prevencion o tratamiento de trastornos del aprendizaje en niños que sufren de trastornos de deficit de atencion/hiperactividad.
Calne Parkinsonism—physiology and pharmacology
HK1028546B (en) Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders
RU2468813C1 (ru) Средство для профилактики или лечения острых и хронических нарушений мозгового кровообращения, применение и способ лечения
ES2327721T3 (es) Compuestos de carbamato para uso en la prevencion o tratamiento del dolor neuropatico.
MXPA00000441A (en) Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders